Abstract:Loss-of-function mutations in methyl-CpG binding protein 2 (MECP2) cause Rett syndrome, a postnatal neurodevelopmental disorder that occurs in ~1/10,000 live female births. MeCP2 binds to methylated cytosines across genomic DNA and recruits various partners to regulate gene expression. MeCP2 has been shown to repress transcription in vitro and interacts with co-repressors such as the Sin3A and NCoR complexes. Based on these observations, MeCP2 has been largely considered as a repressor of transcription. However, a mouse model of RTT displays many down-regulated genes, and those same genes are up-regulated in a MECP2 duplication mouse model. Furthermore, TCF20, which has been associated with transcriptional activation, have recently been identified as a protein interactor of MeCP2. These data broaden the potential functions of MeCP2 as a regulator of gene expression. Yet, the molecular mechanisms underlying MeCP2-dependent gene regulation remain largely unknown. Here, using a human MECP2 gain-of-function Drosophila model, we screened for genetic modifiers of MECP2-induced phenotypes. Our approach identified several subunits of the Drosophila super elongation complex, a P-TEFb containing RNA polymerase II (RNA pol II) elongation factor required for the release of promoter-proximally paused RNA pol II, as genetic interactors of MECP2. We discovered that MeCP2 physically interacts with the SEC in human cells and in the mouse brain. Furthermore, we found that MeCP2 directly binds AFF4, the scaffold of the SEC, via the transcriptional repression domain. Finally, loss of MeCP2 in the mouse cortex caused reduced binding of AFF4 specifically on a subset of genes involved in the regulation of synaptic function, which also displayed the strongest decrease in RNA pol II binding in the genebody. Taken together, our study reveals a previously unrecognized mechanism through which MeCP2 regulates transcription, providing a new dimension to its regulatory role in gene expression.

Emerging physiological and pathological roles of MeCP2 in non-neurological systems

MeCP2: Multifaceted Roles in Gene Regulation and Neural Development

MeCP2 and neurodevelopmental disorders

MeCP2-Related Diseases and Animal Models

Downregulation of CNPase in a MeCP2 Deficient Mouse Model of Rett Syndrome.

MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription

MeCP2 links heterochromatin condensates and neurodevelopmental disease

Research Progress of Rett Syndrome Causing Gene MECP2-The Structure, Function and Modulation of MECP2

A novel pathogenic mutation of MeCP2 impairs chromatin association independent of protein levels

Regulation Mechanism and Research Progress of MeCP2 in Rett Syndrome

MeCP2 Interacts with the Super Elongation Complex to Regulate Transcription

Overexpression of methyl-CpG binding protein 2 impairs T(H)1 responses.

Loss of O-GlcNAcylation on MeCP2 at Threonine 203 Leads to Neurodevelopmental Disorders

Manipulations of MeCP2 in Glutamatergic Neurons Highlight Their Contributions to Rett and Other Neurological Disorders.

Regulation of mRNA splicing by MeCP2 via epigenetic modifications in the brain

Methyl-CpG Binding Protein 2 in Alzheimer Dementia

Dysregulated Cortical Synaptic Plasticity under Methyl-Cpg Binding Protein 2 Deficiency and Its Implication in Motor Impairments

SUMOylation of MeCP2 is essential for transcriptional repression and hippocampal synapse development.

Human MeCP2 binds to promoters and inhibits transcription in an unmethylated S. cerevisiae genome

MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex.

MeCP2 prevents age‐associated cognitive decline via restoring synaptic plasticity in a senescence‐accelerated mouse model